Trial intelligence / Profile preview

Phase II Open-Label Study of Capmatinib in MET Exon 14 Mutated NSCLC With Brain Metastases

2020-002288-69Phase 2Completed

Sponsor

Novartis

Start

Jul 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1